167 related articles for article (PubMed ID: 17103336)
21. Isothermal calorimetry: a predictive tool to model drug-propellant interactions in pressurized metered dose systems.
Ooi J; Gaisford S; Boyd BJ; Young PM; Traini D
Int J Pharm; 2014 Jan; 461(1-2):301-9. PubMed ID: 24325938
[TBL] [Abstract][Full Text] [Related]
22. Comparative bioavailability of two hydrofluoroalkane formulations of formoterol fumarate both delivered by pressurised metered dose inhaler.
Po CJ; Chandran SS; Syed N; Naidu KR; Rathod M; Sule A; Lulla A; Purandare S
Arzneimittelforschung; 2010; 60(2):81-6. PubMed ID: 20329656
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
[TBL] [Abstract][Full Text] [Related]
24. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
Begat P; Morton DA; Staniforth JN; Price R
Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
[TBL] [Abstract][Full Text] [Related]
25. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
26. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
Wu L; Al-Haydari M; da Rocha SR
Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro performance of three small-volume valved holding chambers with beclomethasone/formoterol pressurized metered dose inhaler.
Goncalves TM; Alhanout K; Nicolay A; Dubus JC; de Santana DP; Andrieu V
J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):223-7. PubMed ID: 23094686
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
[TBL] [Abstract][Full Text] [Related]
29. Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope.
Young PM; Price R; Lewis D; Edge S; Traini D
J Colloid Interface Sci; 2003 Jun; 262(1):298-302. PubMed ID: 16256608
[TBL] [Abstract][Full Text] [Related]
30. Hollow porous particles in metered dose inhalers.
Dellamary LA; Tarara TE; Smith DJ; Woelk CH; Adractas A; Costello ML; Gill H; Weers JG
Pharm Res; 2000 Feb; 17(2):168-74. PubMed ID: 10751031
[TBL] [Abstract][Full Text] [Related]
31. Modeling and Understanding Combination pMDI Formulations with Both Dissolved and Suspended Drugs.
Stein SW; Sheth P; Younis US; Mogalian E; Myrdal PB
Mol Pharm; 2015 Sep; 12(9):3455-67. PubMed ID: 26258647
[TBL] [Abstract][Full Text] [Related]
32. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Medication Velocity and Size Distribution from Pressurized Metered-Dose Inhalers by Phase Doppler Anemometry.
Alatrash A; Matida E
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):501-513. PubMed ID: 27504720
[TBL] [Abstract][Full Text] [Related]
34. In vitro characterization of the OptiChamber Diamond valved holding chamber.
Hatley RH; von Hollen D; Sandell D; Slator L
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27 Suppl 1():S24-36. PubMed ID: 25054480
[TBL] [Abstract][Full Text] [Related]
35. Generating monodisperse pharmacological aerosols using the spinning-top aerosol generator.
Biddiscombe MF; Barnes PJ; Usmani OS
J Aerosol Med; 2006; 19(3):245-53. PubMed ID: 17034300
[TBL] [Abstract][Full Text] [Related]
36. The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive-adhesive force balance approach.
Hooton JC; Jones MD; Harris H; Shur J; Price R
Drug Dev Ind Pharm; 2008 Sep; 34(9):974-83. PubMed ID: 18622874
[TBL] [Abstract][Full Text] [Related]
37. Modulite: a simple solution to a difficult problem.
Lewis DA; Ganderton D; Meakin BJ; Brambilla G
Respiration; 2005; 72 Suppl 1():3-5. PubMed ID: 15915006
[TBL] [Abstract][Full Text] [Related]
38. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler.
Saadat A; Zhu B; Haghi M; King G; Colombo G; Young PM; Traini D
J Pharm Pharmacol; 2014 May; 66(5):639-45. PubMed ID: 24329164
[TBL] [Abstract][Full Text] [Related]
39. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
Kaialy W; Ticehurst M; Nokhodchi A
Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
[TBL] [Abstract][Full Text] [Related]
40. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions.
Akapo S; Gupta J; Martinez E; McCrea C; Ye L; Roach M
Ann Pharmacother; 2008 Oct; 42(10):1416-24. PubMed ID: 18780805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
